# BioNTech Agrees to Buy Scholar Rock’s FDA Voucher for $205 Million By John Kim Canonical URL: https://www.tokenpost.com/news/business/53980 Published: 2026-11-11T13:07:57.000Z Updated: 2026-11-11T13:07:57.000Z Section: Business > BioNTech plans to use the voucher for a future filing involving an asset in its late-stage oncology pipeline. BioNTech announced Tuesday, Nov. 10, that it had agreed to pay $205 million for Scholar Rock’s U.S. Food and Drug Administration (FDA) priority review voucher, which it plans to use to speed review of a future oncology filing. The planned application would involve an asset in BioNTech’s late-stage oncology pipeline. A priority review voucher gives one application priority review, shortening the FDA’s target review timeline. The agreement is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act. Payment is due upon closing. The $205 million price is $2 million higher than the $203 million price in [Ultragenyx’s voucher sale](). ## Links in this article - [Ultragenyx’s voucher sale](https://www.tokenpost.com/news/business/31861)